REG - Scancell Hlds - Result of AGM <Origin Href="QuoteRef">SCLP.L</Origin>
RNS Number : 3096TScancell Holdings Plc11 October 201711 October 2017
Scancell Holdings Plc
("Scancell" or the "Company")
Results of AGM
Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that all resolutions proposed at the Annual General Meeting were duly passed.
For Further Information:
Dr John Chiplin, Executive Chairman
Dr Richard Goodfellow, CEO
Scancell Holdings Plc
+1 858 900 2646
+44 (0) 20 3727 1000
Freddy Crossley (Corporate Finance)
Tom Salvesen (Corporate Broking)
Panmure Gordon & Co
+44 (0) 20 7886 2500
Mo Noonan/Simon Conway
FTI Consulting
+44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms.
Scancell's first ImmunoBody, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
This information is provided by RNSThe company news service from the London Stock ExchangeENDRAGGIBDGBSBBGRB
Recent news on Scancell Holdings
See all newsREG - Scancell Hlds - Notice of AGM
AnnouncementREG - Scancell Hlds - Results Year Ended 30 April 2024
AnnouncementREG - Scancell Hlds - Notice of Final Results
AnnouncementREG - Scancell Hlds - Strategic Partnership with PharmaJet
AnnouncementREG - Scancell Hlds - Scancell to attend upcoming conferences
Announcement